Patrick Campbell

Applying a statistical model to estimate the effects of reducing sodium intake at a population level in Australia, investigators suggest adherence to World Health Organization benchmarks could prevent 6900 deaths from CVD, CKD, and stomach cancers annually.

Using data from 2 large prospective studies, a Harvard-led team estimates the impact of adherence to a group of healthy eating patterns on risk of all-cause and cause-specific mortality.

Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.

Data from a 2019 survey of more than 5000 cardiologists across the globe suggests 28% of the field may be experiencing some form of mental health condition, with results also shedding light on predictors of mental health conditions.

Using data from more than 25,000 preschool-aged children in Sweden provides an overview in trends of weight gain and BMI changes that may have impacted pediatric populations during the COVID-19 pandemic.

Using real-world data from the US, Japan, and Sweden provides insight into contemporary trends in GDMT use, including initiation, uptitration, and discontinuation, following hospitalization among patients with heart failure with reduced ejection fraction.

Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.

Released on January 3, the American College of Physician's living osteoporosis guideline represents the organization's first update on the topic since 2017 and includes 6 specific recommendations for pharmacologic management of osteoporosis or low bone mass.

Jesse Morse, MD, a sports medicine specialist, discusses commotio cordis and how to effectively communicate with athletes and parents of young athletes about the diagnosis in the wake of an incident where a player collapsed during a recent NFL game.

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.

As physician demands continue to climb in the high-demand specialty, patient-reported outcomes have emerged as a viable tool in assessment and care.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

Reflections on a century's worth of developments toward a major breakthrough in T1D this year.

A systematic review and meta-analysis assessing more than a dozen double-blind, placebo-controlled trials evaluating cannabis-based products for pain relief suggest these studies were the recipient of a disproportionate level of media coverage that was not associated with the results of each study.

On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.

A trial comparing a 1-week methotrexate hold following seasonal influenza vaccination against the standard 2-week hold among patients with rheumatoid arthritis using methotrexate suggests there were no significant differences in positive vaccine response with either approach.

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.

A pair of studies leveraging NIS data detail the risk of cardiovascular complications during delivery admissions among pregnant persons with a history of systemic lupus erythematosus or use of assisted reproductive technologies relative to their counterparts who did not.

Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.

Viet Le, PA-C, discusses the results of a study examining characteristics and outcomes among pregnant statin users from EHR data recorded at Intermountain Healthcare medical centers.

Results of the CTS-AMI study presented at AHA 22 suggests tongxiluo, which is an herbal medicine compound used in China, could reduce risk of cardiac events and mortality following a heart attack.

A substudy of the PRO-HF study indicates incorporation of KCCQ-12 scores was associated with an improved patient experience and a greater understanding of symptoms.

Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.

Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.

An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.

Published on October 13, the latest scientific statement from the American Heart Association highlights the current role of patient-reported outcome measures in the management of peripheral artery disease as well as future considerations for optimizing this role and benefits in care.